DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Objective: Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer (NSCLC), but no direct Mcl-1 inhibitor is currently available for clinical use. Thus, novel therapeutic strategies are urgently needed to target Mcl-1 and sensitize the anti-NSCLC activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yangling, Zhou, Dongmei, Xu, Shuang, Rao, Mingjun, Zhang, Zuoyan, Wu, Linwen, Zhang, Chong, Lin, Nengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309455/
https://www.ncbi.nlm.nih.gov/pubmed/32587776
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309455/
https://www.ncbi.nlm.nih.gov/pubmed/32587776
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0380

Ejemplares similares